Creo Medical Advances Cancer Treatment Portfolio and Boosts Efficiency

Creo Medical (LSE:CREO) has reported notable progress across both its clinical programs and operational performance. The company has begun clinical studies for its MicroBlate Flex device, marking a key step forward in expanding its cancer treatment portfolio. At the same time, operational efficiency has improved, with costs reduced by 24%.

A strategic transaction — the sale of a 51% stake in CME to Micro-Tech — has further strengthened Creo’s commercial platform and balance sheet. While overall sales declined, revenue from continuing operations rose by 40%, reflecting greater clinical adoption of its devices. Management maintains a positive outlook, citing expectations of sustained revenue growth and future cashflow self-sufficiency.

Despite these advances, the company’s broader financial picture remains challenging, with declining overall revenues and continued losses weighing on results. Technical analysis points to a mixed outlook, showing some near-term positive momentum, but the valuation remains constrained by negative earnings. With no recent earnings calls or corporate updates, external events currently have little influence on sentiment.

About Creo Medical

Creo Medical is a medical technology company specializing in advanced energy-based devices for cancer treatment. Its MicroBlate technology is designed for tumor ablation across multiple cancers, including lung, pancreatic, liver, kidney, and bladder. The company is focused on accelerating clinical adoption of its innovations while expanding access to next-generation oncology solutions.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.